SCHEMBL16649109

SCHEMBL16649109

CC[C@@]1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3cc(O)c(F)cc3nc2-1

nearest known ligand 0.78

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TOP1 P11387 18/20 0.78
▸ MEN1 O00255 4/20 0.75
▸ KMT2A Q03164 4/20 0.75
▸ SMN1; SMN2 Q16637 4/20 0.75
▸ ALDH1A1 P00352 4/20 0.75
▸ KDM4E B2RXH2 3/20 0.75
▸ CYP3A4 P08684 2/20 0.75
▸ HBB P68871 2/20 0.75
▸ DDX5 P17844 1/20 0.75
▸ CASP1 P29466 1/20 0.75
▸ CASP7 P55210 1/20 0.75
▸ GLA P06280 3/20 0.72
▸ TP53 P04637 2/20 0.72
▸ HPGD P15428 2/20 0.72
▸ STAT6 P42226 1/20 0.72
▸ CHEK1 O14757 1/20 0.72
▸ HDAC3 O15379 1/20 0.72
▸ ABCC4 O15439 1/20 0.72
▸ GMNN O75496 1/20 0.72
▸ LMNA P02545 1/20 0.72

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3138027 0.94 TOP1 (0.82) TOP1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL3513607 0.93 TOP1 (0.86) TOP1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL27764694 0.93 TOP1 (0.86) TOP1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL30805390 0.91 TOP1 (0.78) TOP1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL22598074 0.91 TOP1 (0.78) TOP1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL34463611 0.91 TOP1 (0.78) TOP1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL30538213 0.90 TOP1 (0.82) TOP1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL26405346 0.90 TOP1 (0.82) TOP1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL30805404 0.89 TOP1 (0.74) TOP1MEN1KMT2ASMN1; SMN2ALDH1A1
SCHEMBL16648871 0.89 TOP1 (0.74) TOP1MEN1KMT2ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4426727-A2 SPECIFIC CONJUGATION OF AN ANTIBODY Hangzhou Dac Biotech Co., Ltd. (CN) 2024-09-11 — — EP disclosed
EP-4426729-A1 SPECIFIC CONJUGATION FOR AN ANTIBODY-DRUG CONJUGATE Hangzhou Dac Biotech Co., Ltd. (CN) 2024-09-11 — — EP disclosed
US-20230241241-A1 CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2023-08-03 — — US disclosed
WO-2023078273-A1 SPECIFIC CONJUGATION FOR AN ANTIBODY-DRUG CONJUGATE HANGZHOU DAC BIOTECH CO., LTD. (CN) 2023-05-11 — — WO disclosed
WO-2022078524-A4 SPECIFIC CONJUGATION OF AN ANTIBODY HANGZHOU DAC BIOTECH CO., LTD. (CN) 2022-12-08 — — WO disclosed
WO-2022078524-A2 SPECIFIC CONJUGATION OF AN ANTIBODY HANGZHOU DAC BIOTECH CO., LTD. (CN) 2022-04-21 — — WO disclosed
US-9458170-B2 Compound of camptothecin and preparation and use thereof YULIANG LI (CN) 2016-10-04 — — US disclosed
US-9458170-B2 Compound of camptothecin and preparation and use thereof YULIANG LI (CN) 2016-10-04 — — US disclosed
US-9458170-B2 Compound of camptothecin and preparation and use thereof YULIANG LI (CN) 2016-10-04 — — US disclosed
US-20150166559-A1 COMPOUND OF CAMPTOTHECIN AND PREPARATION AND USE THEREOF Li, Yuliang (CN) 2015-06-18 — — US disclosed
US-20150166559-A1 COMPOUND OF CAMPTOTHECIN AND PREPARATION AND USE THEREOF Li, Yuliang (CN) 2015-06-18 — — US disclosed
US-20150166559-A1 COMPOUND OF CAMPTOTHECIN AND PREPARATION AND USE THEREOF Li, Yuliang (CN) 2015-06-18 — — US disclosed
EP-2862571-A1 COMPOUND OF CAMPTOTHECIN AND PREPARATION AND USE THEREOF Li, Yuliang (MN) 2015-04-22 — — EP disclosed
EP-2862571-A1 COMPOUND OF CAMPTOTHECIN AND PREPARATION AND USE THEREOF Li, Yuliang (MN) 2015-04-22 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150166559-A1 COMPOUND OF CAMPTOTHECIN AND PREPARATION AND USE THEREOF TOP2A, TOP2B, TYMP TOP1 4/4885MEN1 422/4885KMT2A 4271/4885
US-20230241241-A1 CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS CD4, DCLRE1A, TOP1 TOP1 3/4885MEN1 188/4885KMT2A 2544/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback